Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an, Shaanxi 710061, PR China.
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Center, Xi'an, Shaanxi 710061, PR China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an, Shaanxi 710061, PR China; Genetic and Eugenic Laboratory, Baoji Maternal and Child Health Hospital, Baoji, Shanxi 721099, PR China.
Mol Immunol. 2022 Dec;152:129-139. doi: 10.1016/j.molimm.2022.10.014. Epub 2022 Nov 2.
Non-alcoholic fatty liver disease (NAFLD) is increasingly affecting human health and the economy worldwide due to various factors. Here, we found that the expression of TGF-β1 and TLR2 was significantly up-regulated in liver samples from both rats and mice nonalcoholic steatohepatitis (NASH) models. By constructing corresponding cell model, we found that TGF-β1 challenge can positively regulate the expression of TLR2 and p-Smad2/3, and the dual luciferase reporter gene system and EMSA assay confirmed the existence of Smad3 binding site (-916 ∼ -906) in the promoter region of TLR2. The overexpression and interference changes of Smad2/3 further verified the above experimental results. Taken together, these findings suggest that TGF-β1 promotes TLR2 transcription and its target gene expression via Smad3, leading to malignant exacerbation of liver inflammation in NASH, which provides new insights into the treatment of NASH.
非酒精性脂肪性肝病(NAFLD)由于多种因素的影响,正在日益影响全球人类健康和经济。在这里,我们发现 TGF-β1 和 TLR2 的表达在大鼠和小鼠非酒精性脂肪性肝炎(NASH)模型的肝组织样本中均显著上调。通过构建相应的细胞模型,我们发现 TGF-β1 可正向调节 TLR2 和 p-Smad2/3 的表达,双荧光素酶报告基因系统和 EMSA 实验证实了 TLR2 启动子区域存在 Smad3 结合位点(-916∼-906)。Smad2/3 的过表达和干扰变化进一步验证了上述实验结果。综上,这些发现表明 TGF-β1 通过 Smad3 促进 TLR2 的转录及其靶基因表达,导致 NASH 中肝脏炎症的恶性加剧,为 NASH 的治疗提供了新的见解。